BRIAN L. BURNETTE
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- Escanaba, MI
- NPI
- 1952523680
- Received
- $6,841 in 6 records, 2019 to 2025 ($91 general, $6,750 research)
- As principal investigator
- $189,761 of research payments to others in 26 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 1 | $26 |
| 2023 | General payment | 1 | $24 |
| 2021 | General payment | 3 | $39 |
| 2019 | Research payment | 1 | $6,750 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $6,750 | 2019 |
| Acrotech Biopharma Inc. | 2 | $27 | 2021 |
| Daiichi Sankyo Inc. | 1 | $26 | 2024 |
| Incyte Corporation | 1 | $24 | 2023 |
| Gilead Sciences, Inc. | 1 | $11 | 2021 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1 | $6,750 |
| Education | 4 | $66 |
| Food and Beverage | 1 | $24 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-04-04 | Daiichi Sankyo Inc. | $26 | Education | In-kind items and services | Enhertu Drug, ONCOLOGY | 2024 | |
| 2023-11-22 | Incyte Corporation | $24 | Food and Beverage | Cash or cash equivalent | PEMAZYRE Drug, Hepatology (Liver, Pancreatic, Gall Bladder) | 2023 | |
| 2021-09-01 | Acrotech Biopharma Inc. | $13 | Education | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2021 | |
| 2021-06-14 | Acrotech Biopharma Inc. | $13 | Education | In-kind items and services | BELEODAQ Drug, ONCOLOGY | 2021 | |
| 2021-06-01 | Gilead Sciences, Inc. | $11 | Education | In-kind items and services | 2021 | ||
| 2019-02-05 | Takeda Pharmaceuticals U.S.A., Inc. | $6,750 | Research payment | Cash or cash equivalent | The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-09-26 | National Marrow Donor Program | ST. VINCENT HOSPITAL | $7,000 | A Phase 3 Study of Teclistamab in Combination with Lenalidomide and Teclistimab Alone versus Lenalidomide Alone in Parti | 2025 |
| 2025-04-03 | E.R. Squibb & Sons, L.L.C. | ASCENSION ST. VINCENT HOSPITAL | $16,125 | Connect MM: The Multiple Myeloma Disease Registry. The purpose of the Connect MM Registry is to explore the natural hist | 2025 |
| 2024-09-05 | E.R. Squibb & Sons, L.L.C. | ASCENSION ST. VINCENT HOSPITAL | $4,875 | Connect MM The Multiple Myeloma Disease Registry | 2024 |
| 2024-08-07 | E.R. Squibb & Sons, L.L.C. | ST. VINCENT HOSPITAL | $1,500 | Connect MM The Multiple Myeloma Disease Registry | 2024 |
| 2024-05-16 | Celgene Corporation | ASCENSION ST. VINCENT HOSPITAL | $4,125 | Connect MM- The Multiple Myeloma Disease Registry | 2024 |
| 2023-03-24 | Celgene Corporation | ASCENSION ST. VINCENT HOSPITAL | $10,500 | Connect MM- The Multiple Myeloma Disease Registry | 2023 |
| 2022-09-13 | Celgene Corporation | ASCENSION ST. VINCENT HOSPITAL | $11,625 | Connect MM- The Multiple Myeloma Disease Registry | 2022 |
| 2022-05-05 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL OF THE HOSPITAL SISTERS OF THE THIRD ORDER OF ST FRANCIS | $9,412 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2022 |
| 2021-12-31 | Merck Sharp & Dohme LLC | CROWN NCORP | $41 | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2021 |
| 2021-11-26 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL OF THE SISTERS THIRD | $500 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2021 |
| 2021-11-26 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL OF THE SISTERS THIRD | $250 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2021 |
| 2021-10-19 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL OF THE SISTER THIRD | $1,350 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2021 |
| 2021-05-18 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL OF THE HOSPITAL SISTERS | $13,500 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2021 |
| 2021-02-16 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL OF THE HOSPITAL SISTERS OF THIRD | $250 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2021 |
| 2021-02-02 | Celgene Corporation | ST. VINCENT HOSPITAL & HCC | $20,770 | Connect MM- The Multiple Myeloma Disease Registry | 2021 |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL | $500 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL | $500 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 |
| 2020-12-10 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL | $4,725 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 |
| 2020-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL | $3,712 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 |
| 2020-09-16 | Takeda Pharmaceuticals U.S.A., Inc. | ST VINCENT HOSPITAL | $6,075 | A GLOBAL, PROSPECTIVE, NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF PRESENTATION, TREATMENT PATTERNS, AND OUTCOMES IN MULT | 2020 |
| 2020-02-11 | Celgene Corporation | ST. VINCENT HOSPITAL & HCC | $22,125 | Celgene - Connect MM | 2020 |
| 2019-12-19 | Takeda Pharmaceuticals U.S.A., Inc. | PREVEA CLINIC INC | $500 | The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment | 2019 |
| 2019-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | PREVEA CLINIC INC | $12,600 | The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment | 2019 |
| 2019-10-22 | Takeda Pharmaceuticals U.S.A., Inc. | PREVEA CLINIC INC | $5,062 | The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment | 2019 |
| 2019-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | PREVEA CLINIC INC | $4,387 | The Global Multiple Myeloma Registry- A Global, Prospective, Observational Study of Patient Outcomes Following Treatment | 2019 |
| 2019-05-29 | Celgene Corporation | ST. VINCENT HOSPITAL & HCC | $27,750 | Celgene - Connect MM | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Escanaba, MI, county Delta County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Escanaba, MI | County Delta County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 12,354 | 36,813 | 10,077,761 |
| Population, 2020 census P1 | 12,450 | 36,903 | 10,077,331 |
| Median age B01002 | 44.4 | 48.0 | 40.2 |
| Under 18 B01001 | 20.2% | 19.1% | 21.2% |
| 65 and over B01001 | 23.3% | 26.2% | 18.6% |
| Households B11001 | 5,715 | 15,971 | 4,076,369 |
| Foreign born B05002 | 1.6% | 1.0% | 7.2% |
| Median household income B19013 | $45,369 | $57,809 | $72,875 |
| Median family income B19113 | $63,314 | $78,563 | $93,357 |
| Per capita income B19301 | $32,014 | $36,649 | $40,735 |
| Poverty rate B17001 | 17.7% | 12.7% | 13.2% |
| Unemployment rate B23025 | 5.2% | 4.2% | 5.7% |
| Civilian labor force B23025 | 5,214 | 15,743 | 5,018,449 |
| Mean commute (minutes) B08013 | 11.0 | 18.2 | 24.2 |
| Bachelor's degree or higher B15003 | 19.8% | 20.6% | 32.4% |
| Housing units B25001 | 6,464 | 19,845 | 4,622,236 |
| Owner-occupied B25003 | 63.9% | 82.0% | 73.2% |
| Renters B25003 | 36.1% | 18.0% | 26.8% |
| Median home value B25077 | $125,200 | $157,100 | $231,600 |
| Median gross rent B25064 | $657 | $692 | $1,129 |
| White, not Hispanic B03002 | 86.5% | 89.9% | 72.4% |
| Black B03002 | 0.5% | 0.2% | 13.1% |
| Hispanic or Latino B03002 | 2.4% | 1.5% | 5.9% |
| Asian B03002 | 1.0% | 0.5% | 3.4% |
| American Indian and Alaska Native B03002 | 1.2% | 1.5% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Escanaba, MI.
Comments